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Harlequin ichthyosis (HI) is the most severe form of autosomal-recessive, congenital ichthyosis. Affected infants
have markedly impaired barrier function and are more susceptible to infection. Abnormalities in the localization
of epidermal lipids as well as abnormal lamellar granule formation are features of HI skin. Previously, we and
others have shown that mutations in the ABCA12 gene encoding an adenosine triphosphate-binding cassette
(ABC) transporter underlie the skin disease HI. In this study, we have sequenced the ABCA12 gene in an
additional 14 patients and show that all contain mutations, with the majority being either nonsense substitution
or frameshift mutations. Eleven HI patients had bi-allelic ABCA12 mutations, whereas in the remaining three HI
patients in this study, ABCA12 mutations were detected on only one allele by sequencing. In addition, the one
patient from the previous study where no sequence mutations were detected was screened for heterozygous
deletions. A combination of oligonucleotide arrays, multiplex PCR analysis and single-nucleotide polymorph-
ism genotyping revealed a heterozygous intragenic deletion in exon 8. These mutation data establish ABCA12 as
the major HI gene.
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INTRODUCTION
Harlequin ichthyosis (HI, OMIM 242500) is the most severe
and often lethal form of recessive congenital ichthyosis (Hsu
et al., 1989; Moreau et al., 1999; Sarkar et al., 2000). Infants
born with this condition have hard, thick skin covering most of
their body. The skin forms large diamond-shaped plates
separated by deep fissures that restrict movement (Hsu et al.,
1989; Dahlstrom et al., 1995). These skin abnormalities also
affect the shape of the eyelids, nose, lips, and ears. Owing to
the impaired barrier function of the skin, neonates struggle to
control water loss, regulate temperature, and are more
susceptible to infection (Moskowitz et al., 2004). In addition,
the tightened skin can cause breathing difficulties leading to
respiratory failure. In the past, an HI-affected neonate would
often die within days of birth; however, with better intensive
care and possibly the use of oral retinoids, patients now have
an increased chance of survival (Hsu et al., 1989; Moreau
et al., 1999; Elias et al., 2000; Sarkar et al., 2000). HI has been
reported in both sexes and in a variety of ethnic backgrounds.
Our previous study utilized single-nucleotide polymorph-
ism (SNP) array technology to map the HI locus to chromo-
some 2q35 and subsequently demonstrated that mutations in
the ABCA12 gene were a major cause of HI, with 11 out of 12
patients studied harboring bi-allelic ABCA12 mutations
(Kelsell et al., 2005). Another study has independently
associated ABCA12 mutations with HI (Akiyama et al.,
2005). ABCA12 is a member of the adenosine triphosphate-
binding cassette (ABC) superfamily of active transporters.
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Mutations in ABC genes underlie a variety of other diseases,
including cystic fibrosis, Tangier disease, pseudoxanthoma
elasticum, X-linked adrenoleukodystrophy and Dubin–John-
son syndrome (Hovnanian, 2005; Uitto, 2005). Interestingly,
it has been shown that mutations in the first adenosine
triphosphate-binding domain of ABCA12 underlie some
cases of autosomal-recessive lamellar ichthyosis in families
from Africa that showed linkage to chromosome 2q33–34
(Lamellar Ichthyosis type 2, (LI2), OMIM 601277) (Lefevre
et al., 2003). There is evidence to show that ABCA12 is a
lipid-trafficking molecule involved in lamellar body forma-
tion and studies have reported abnormalities in the localiza-
tion of epidermal lipids as well as abnormal lamellar granule
formation in HI skin (Dale et al., 1990; Akiyama et al., 2005).
In addition, the introduction of ABCA12 by gene transfer in
HI keratinocytes increased lamellar granule lipid secretion
(Akiyama et al., 2005).
In this study, we have screened a further 14 unrelated
patients affected with HI for disease-associated mutations in the
ABCA12 gene. In addition to sequence analysis, two different
copy number analyses were performed to detect possible
compound heterozygous exon or multiple exon deletions.
RESULTS
Sequence analysis of the ABCA12 gene
Sequence analysis of all 53 coding exons of the ABCA12
gene revealed likely disease-associated ABCA12 mutations in
all 14 patients described in this study. Examples are shown in
Figure 1 and Table S1 gives the specific details of mutations
found in each patient. Figure 2 shows a summary of HI-
associated ABCA12 mutations found in this and our previous
study. Two patients were compound heterozygotes and nine
were found to have homozygous mutations. In three patients,
mutations were found on one allele only. The majority of
mutations are nonsense substitutions arising from an inserted
premature STOP codon, but four separate single base pair
deletions and one single base pair insertion was detected,
which are likely to result in frameshift mutations. Evidence for
possible founder mutations was found within different ethnic
groups. The UK patients of Caucasian origin, 66 and 96, had
inherited the same mutation in exon 16 (2025delG). The
mutations 7322delC and W1294* were previously identified
in HI patients of Pakistani origin from our other studies
(Kelsell et al., 2005; Rajpar et al., 2005). In addition, the
Native American HI patient D938-01 was homozygous for
the same ABCA12 mutation (W1744* mutation in exon 34) as
previously identified in an unrelated Native American HI
patient from a previous study (Kelsell et al., 2005). Although
the vast majority of HI-associated ABCA12 mutations
identified to date (this study) (Akiyama et al., 2005; Kelsell
et al., 2005) (Figure 2) would result in a truncated protein,
patient 95 was found to contain a homozygous missense
substitution (G1179R) in the first transmembrane domain of
ABCA12. This residue is conserved in mouse, rat, and
a
b
Figure 1. Sequencing and HPLC data from HI affected patients. (a) Sequences from three HI-affected patients along with normal controls. (b) Denaturing
high-performance liquid chromatography traces of exon 24 showing patient 95 (homozygous G1179R), the mother of patient 95 (heterozygous), and
a wild-type control.
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chicken orthologs of ABCA12. His unaffected mother was
heterozygous for this amino-acid substitution. G1179R was
not detected by denaturing high-performance liquid chroma-
tography mutation screening in one hundred unrelated
controls of mixed ethnicity. Functional studies are required
to determine the proposed disease-causing nature of this
mutation.
Multiplex and oligonucleotide array analysis
Two different methodologies were used to assess if single or
multiple exon deletions in ABCA12 accounted for the
‘‘missing’’ mutation(s) in the predicted compound hetero-
zygous HI patients (61, 131, and 96) and, from our previous
study (Kelsell et al., 2005), in patient 50 in whom no ABCA12
mutations were identified. In a compound heterozygous
form, these deletion mutations would be unidentifiable from
a standard PCR reaction and sequencing. The first methodo-
logy was a multiplex PCR in which pools of primers used to
amplify five different ABCA12 exons at a time were used to
look for differences in amplification of each amplicon within
the multiplex reaction. PCR products were resolved and
quantified using Lab-on-a-Chip (Agilent Technologies, Ger-
many) and also by running under size standard conditions on
the WAVE system instrument (Transgenomic, France). The
second method was a customized oligonucleotide array
(Agilent Technologies, Germany) in which every exon of the
ABCA12 gene was represented. To validate both assays, two
control samples were used: DNA from a patient homozygous
for a deletion of exon 23 was mixed 1:1 with control DNA to
generate an artificial exon 23 deletion compound hetero-
zygote and a similar compound heterozygote control was
generated for the homozygous deletion spanning exons
28–53. Both control heterozygous deletions were detected
in the heterozygous form using the two deletion assays (data
not shown). The assays were then performed on the patient
DNA. Both methods clearly detected a previously undetect-
able heterozygous deletion of exon 8 of ABCA12 in patient
50 (Figure 3a and d). The exon 8 deletion was confirmed by
genotyping the DNA of patient 50 and that of her parents with
SNPs mapping in exon 8 and flanking intron (Figure 3f). The
exon 8 deletion was inherited from her mother. Further
molecular studies are required to define this putative
deletion. Surprisingly, the sensitivity of the array methodo-
logy actually identified the single-nucleotide deletion within
exon 16 of ABCA12 in patient 96 (Figure 3e). No other
deletion mutations were identified.
DISCUSSION
The findings from this study firmly establish ABCA12 as the
major gene associated with HI. The increased number of
patients with mutations in the ABCA12 gene provides further
evidence that ABCA12 mutations are the main cause of HI
and will allow prenatal diagnosis and/or pre-implantation
genetic testing to be performed for most if not all HI carriers.
A mutation on only one allele was discovered in three
patients (90, 61, and 921–01). As the disease is recessive, we
assume that there is another mutation on the other allele,
perhaps of a more complex type, such as one in a regulatory
region. We thought it possible that these patients may harbor
heterozygous exon or multiple exon deletions that cannot be
identified with standard sequencing techniques. These
deletions are present in a homozygous form in HI patients
from our previous study (Kelsell et al., 2005). Unfortunately,
skin biopsies were not available from these three patients to
assay for ABCA12 protein levels. Large intragenic gene
deletions have been reported in other ABC genes associated
with disease. For example, in ABCC6 associated with
pseudoxanthoma elasticum, a deletion of exons 23–29 was
reported in 11% of patients screened (Miksch et al., 2005).
Indeed, other ABCC6 deletions have been described, which
completely span the ABCC6 locus. To investigate for possible
heterozygous exon deletions in ABCA12, we designed two
laboratory investigations: multiplexing and peak height
comparisons and the second was a comparative genomic
hybridization (CGH) array approach. Both methods clearly
detected a heterozygous deletion of exon 8 of ABCA12 from
patient 50. Unexpectedly, the array methodology also
identified the single-nucleotide deletion in exon 16 of
ABCA12 from patient 96 previously found by sequencing.
The 60mer oligonucleotide designed for exon 16 actually
spans this G nucleotide deletion. This array-based mutation
approach clearly will have applications for mutation analysis
in other diseases in which heterozygous exon/intra–exon
deletions are common.
W199* and Q228*
Q354*
Y377* R714*
R1297*
G1179R
W1294* Q2161*
R1881*
W1744*
R2203*
D2363N
Del 28−53
Del 23
Del T
Del 8
Del G Del A Del CG Del C
Ins T
ABCA12
Exon 6 8 9 10 16 17 23 24 27 28 33 34 37 42 44 47 49 53
Figure 2. A schematic of the ABCA12 gene showing the location of HI mutations found. Our previously published mutations are shown in blue, whereas novel
mutations are shown in black. Deletions and insertions are shown below the gene, whereas nonsense and missense mutations are shown above. Exons are
shown in red.
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Mutations in the ABCA12 gene have also been identified
in a subgroup of patients from Africa with LI2 (Lefevre et al.,
2003). The mutations in ABCA12 associated with LI2 have so
far been shown to occur between exons 28 and 31, which
correspond to the first nucleotide-binding fold (NBF1) located
between amino acids 1370 and 1554. None of the mutations
in this or the previous study have been found in the region of
the NBF1. However, the vast majority of HI mutations found
are truncations predicted to disrupt, at least, the C terminal
end of the protein where the second NBF2 is located between
amino acids 2282 and 2467. In our previous study, the only
amino-acid substitution that was not a premature STOP
codon was D2363N (Kelsell et al., 2005). In contrast to
ABCA12-associated LI2, this mutation is located directly in
the second NBF region of the protein. It is therefore likely that
missense mutations in these different regions of the gene
determine the severity of the ichthyosis either LI2 if in NBF1
or the more severe HI if in NBF2. In this study, we have
identified another missense substitution (G1179R) in exon 24
(homozygous in patient 95) that would substitute a glycine
(uncharged polar residue) for an arginine (positively charged
residue) in the first transmembrane domain of the protein.
This variant was not seen in 200 control chromosomes, but
the functional effect of this change requires further char-
acterization.
It has been proposed that HI can be divided into three
subtypes based on the expression patterns of keratin 16 and
profilaggrin as well as the presence of keratohyalin granules
(Dale et al., 1990). In this study, we analyzed one patient
(923-01) classified as type 1 under this system (all the rest
were type IIs) and they were homozygous for a stop mutation
in exon 6. This is a similar type of mutation seen in most HI
patients that would lead to a severely truncated protein if
expressed. This suggests that other factors unrelated to the site
and type of mutation in ABCA12 account for this immuno-
histochemical classification
A key question raised is why is there reduced and
immature lamellar granules in HI skin? Other ABC transpor-
ters including ABCA7 are also expressed in the skin and have
been shown to be involved in the transportation of lipids in
the epidermis. Over expression of ABCA7 in HeLa cells
results in an increased expression of intracellular and cell
surface ceramide as well as intracellular phosphatidylserine.
It is suggested by the authors that ABCA7 may play a
functional role in lamellar body lipid homeostasis in the
epidermis (Kielar et al., 2003). In addition, the transporters
ABCC1, ABCC3, and ABCC4 translocate amphiphilic anions,
such as conjugates of lipophilic compounds with glutathione,
glucuronate, and sulfate. It has also been suggested that
ABCB1 and ABCG1 are involved in phospholipid transport,
a
b
c
d e
f
Figure 3. Details of heterozygous exon deletions. (a–c) Details of multiplex PCR from patient 50 and two controls along with (d) the Agilent oligo array data
showing a reduction in copy number in exon 8 of patient 50, and (e) the presence of the known heterozygous G deletion in patient 96. (f) Deleted
oligonucleotides are indicated by arrows. Pedigree of patient 50 with genotypes of exon 8 SNP (c.888 G4A (V296V)) and an intron 8 SNP marker (c.985þ 85
T4C). The genotypes clearly show non-maternal inheritance supportive of a maternal deletion spanning exon 8. Deleted SNPs are depicted as .
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whereas ABCB1 and ABCG1 may be involved in the
translocation of cholesterol (Kielar et al., 2003). Therefore if
these, and other, ABC transporters are expressed in the skin
and are involved in lipid transport, why is it not possible for
them to compensate for the lack of ABCA12 found in HI?
Interestingly, the eletron microscopy features of HI lamellar
granules grossly resemble those seen in the neurocutaneous
syndrome (CEDNIK: cerebral dysgenesis, neuropathy,
ichthyosis, and palmoplantar keratoderma) caused by a
mutation in a gene coding for a SNARE protein (Sprecher
et al., 2005), suggesting a possible link with abnormal lipid
cargo loading of the vesicles.
In conclusion, we have screened a further 14 unrelated
patients affected with HI and identified likely disease-
associated mutations in the ABCA12 gene. The majority of
mutations are predicted to cause nonsense substitution or
frameshift mutations. Patients without biallelic ABCA12
mutations following sequence analysis (this and our previous
study: Kelsell et al. (2005)) were re-assessed using two copy
number molecular strategies: a multiplex PCR, the other a
CGH-based array platform. Indeed, the patient from our
previous study (Kelsell et al., 2005) in which no mutations
were found by sequencing, was found by these methods to
have exon 8 heterozygously deleted. From this study and our
other studies, 22/26 unrelated HI patients of various
ethnicities that we have analyzed by sequencing harbor bi-
allelic mutations in the ABCA12 gene. Four of twenty-six
patients have mutations found by sequencing and copy
number analysis on one allele only (Kelsell et al., 2005;
Rajpar et al., 2005). Other plausible gene mutations that have
not been assessed are inversions, promoter mutations and
splice site mutations embedded deep in intronic sequence. In
addition, disease-associated ABCA12 mutations in four other
HI cases have also been described (Akiyama et al., 2005).
These mutation data clearly emphasize that ABCA12 muta-
tions are the major genetic cause of HI. In addition, the
identification of a heterozygous whole exon deletion in one
patient highlights the requirement for such mutations to be
taken into account when offering prenatal testing for HI.
MATERIALS AND METHODS
Clinical features and patient origins
Fourteen families with individuals affected with HI were used in this
study: eight from the US, one from Ireland, five from Great Britain,
and one from Israel. All patients and their families consented to take
part in this study. Ethical approval was obtained from the relevant
Local Research Ethics Committees. The clinical phenotype was
verified as HI by at least two clinicians and relevant clinical
information is shown in Table S2. Patient 50 was described in our
previous study (Kelsell et al., 2005). The study was conducted
according to The Declaration of Helsinki Principles.
Sequence and denaturing high-performance liquid
chromatography analysis of ABCA12
Primer design, PCR, and sequencing conditions used were the same
as those described previously (Lefevre et al., 2003; Kelsell et al.,
2005). The primers used for denaturing high-performance liquid
chromatography analysis of G1179R in exon 24 are forward primer
(50-CGGACTACAGCTTCTCGGTTA-30) and reverse primer (50-AAT
TTCCCACTCTGCCATTC-30) to amplify a product of 205 bp. Briefly,
PCR products covering each of the 53 exons and intron boundaries
were purified using ExoSAP-IT (Amersham Pharmacia Biotech, UK).
Each exon was then sequenced in both directions. Sequencing was
carried out using ABI BigDye Terminator reagents (Applied
Biosystems, CA) and an ABI 3700 sequencer. Sequencing reaction
conditions were 5ml of purified product, 1ml of BigDye Terminator
v.3.1, 3ml of Better Buffer (Microzone, UK), and 1ml water. Cycling
conditions consisted of 25 cycles of 941C for 30 seconds, 501C for
15 seconds, and 601C for 2 minutes. Reactions were precipitated on
ice for 15 minutes following the addition of 2 ml of 3 M NaOAc (pH
5.2) and 50ml ethanol. Sequence analysis was performed using
Phred, Prap, and Consed. Variants were detected using reference
sequence (cDNA reference sequence NM_173076 and genomic
sequence for intronic variants) taken from the Ensembl Genome
Browser (Ewing and Green, 1998). Denaturing high-performance
liquid chromatography (Transgenomic WAVE system, France) was
used to assess whether the exon 24 sequence variant G1179R found
in patient 95 was likely to be a mutation or a polymorphism. The
205 bp fragment of exon 24 was analyzed in 100 control individuals
plus patient and maternal samples, which are homozygous and
heterozygous for G1179R, respectively. Five microliters of each PCR
product was injected under the mutation detection program with an
oven temperature of 591C and a flow rate of 0.9. Site of mutation is
based on the first nucleotide of the translation initiation codon ATG
using cDNA reference sequence NM_173076.
Oligonucleotide microarray
The Human Genome CGH Microarray 44B (Agilent Technologies,
Germany) contained B43,000 in situ synthesized 60-mer oligo-
nucleotide probes that span coding and non-coding sequences with
an average spatial resolution of B35 kb. The probes were designed
in silico based on the National Center for Biological Information
genome build 35 and were optimized for high-resolution array-
based CGH. The catalog array was customized using the Agilent on-
line design service eArray, by adding a further 73 probes (each
replicated five times) designed specifically to span the ABCA12 gene
at chromosome 2q35 increasing the average spatial resolution in that
region to B1.7 kb. For each CGH hybridization, 3 mg of genomic
DNA from the reference control (46, XY) and the corresponding
experimental sample were digested with AluI (25 U) and RsaI (25 U)
(Promega, UK) for 2 hours at 371C. Individual reference and
experimental samples were then purified using the QIAprep Spin
Miniprep Kit (Qiagen, UK). Using the total amount of purified
restricted DNA eluted, labeling reactions were performed with the
BioPrime Array CGH Genomic Labeling Module (Invitrogen, UK)
according to the manufacturer’s instructions in a volume of 50 ml.
Sixty micromolar Cy5-dUTP (for the experimental sample) or Cy3-
dUTP (for the XY male reference) (Perkin-Elmer, Wellesley, MA) was
added and vice versa for the corresponding dye-swap arrays.
Experimental and reference targets for each hybridization were
combined and purified using a Microcon YM-30 column (Millipore,
Billerica, MA) to a final volume of 150 ml. The labeled targets were
mixed with 50 ml of human Cot-1 DNA (Invitrogen, UK) and 50 ml of
10 blocking agent (Agilent Technologies), and then mixed with an
equal volume of Agilent 2 Oligo aCGH Hybridization buffer.
Before hybridization to the array, the 500 ml hybridization mixtures
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were denatured at 951C for 5 minutes and incubated at 371C for
30 minutes. To remove any precipitate, the mixture was centrifuged
at B17,000 g for 1 minutes and then 490ml of the sample was
applied to the array. Using an Agilent microarray hybridization
chamber, the hybridization was carried out for 40 hours at 651C in a
rotating oven (Robbins Scientific, Mountain View, CA) at 20 r.p.m.
The hybridization chambers were then disassembled in Agilent
Oligo aCGH Wash Buffer 1 at room temperature and the arrays
washed for 5 minutes at room temperature in fresh wash buffer 1,
followed by 1 minute at 371C in Agilent Oligo aCGH Wash Buffer 2
(prewarmed to 371C overnight). The slides were removed from wash
buffer 2 slowly (5–10 seconds) after which time they were
completely dry and were then scanned using an Agilent G2565BA
DNA microarray scanner. Microarray images were analyzed by
using Feature Extraction software (version 8.1, Agilent Technologies)
and the data visualized using CGH Analytics software (version 3.2,
Agilent Technologies).
Multiplex PCR analysis by lab-on-a-chip electrophoresis
For the separation of multiplex PCR products, DNA 1000 LabChip
Kits and the 2100 bioanalyzer (Agilent Technologies, Germany)
were used according to the manufacturer’s instructions. In brief, 9 ml
gel–dye mix was added to the chip and then pressurized through the
microchannels. Marker solution and DNA 1000 ladder were added
then 1ml of each PCR reaction was pipetted into each of the 12
sample wells of the prepared chip. After vortexing, the chip was
placed in the Agilent 2100 bioanalyzer and run using the DNA 1000
assay. Electrophoresis of the 12 samples took 30 minutes including
fragment analysis that was carried out using Agilent’s 2100 Expert
software. Electropherograms were overlaid to compare PCR patterns
derived from patient and control DNA. Additional separation and
peak height comparison was performed on the Transgenomic WAVE
instrument under non-denaturing conditions.
SNP marker analysis
PCR products were sequenced using Dye Terminator Cycle
Sequencing Quick Start Kit (Beckman Coulter, High Wycombe,
Buckinghamshire, UK) and run on the Beckman Coulter CEQ8000
Genetic Analysis System. The two relevant SNPs in the region shown
to be heterozygously deleted in the affected member of the family
(patient 50) are: exon 8, c.888 G4A (V296V) and intron 8,
c.985þ 85 T4C.
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